Circulating Tumor Cells Market Top Players, Segments, Cost Structure, Demand by 2030| Top Industry Leaders Apocell, Vitatex Inc.

 

Circulating Tumor Cells Market Growth & Trends

The global circulating tumor cells market size is expected to reach USD 27.55 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 13.34% from 2023 to 2030. Many potential applications of circulating tumor cells (CTCs) in pre-diagnosis, pretreatment, and intra- and post-treatment provide lucrative growth opportunities to players involved in the development of CTC enrichment and isolation products. Research organizations are involved in activities, which are aimed at developing CTC-based tests to improve cancer diagnosis in terms of efficiency and speed. Furthermore, the growing demand for personalized medicines and growing research for drug development is anticipated to tailor treatment for individuals at the genetic and molecular levels. For instance, according to the research study conducted by Indiana University School of Medicine in October 2021, the presence of CTC and circulating tumor DNA (ctDNA) in the plasma of women who have received pre-surgery chemotherapy for triple-negative breast cancer is one of the important indicators to predict disease recurrence. Thus, these factors are anticipated to drive the market growth over the forecast period.

Moreover, the rising demand for minimally invasive diagnostic treatments is anticipated to impel funds from key stakeholders in this area. CTC-based liquid biopsy tests lead to limited trauma and allow speedy recovery attributing to its non-invasive nature. Furthermore, it assists in minimally invasive screening of cancer formerly opting for complicated surgical treatments, which include surgical removal of tumors, chemotherapy, and radiotherapy, thus positively impacting the adoption of circulating tumor cells.

The limited applicability of these cells in rare cancers has hampered revenue growth to a certain extent. Circulating tumor cells are not applicable to tumors characterized by EpCAM negativity or low expression, such as neurogenic cancers. For instance, there is negligible evidence for the characterization of circulating tumor cells for sarcoma. Conversely, numerous methods are being studied for the isolation of these cells, which include methods based on epithelial antigen-targeted antibodies, anticipating to overcome these challenges in the coming years.

However, in recent years there has been a push for practical application, largely as a result of a wave of large players centralizing the technology through acquisitions and numerous partnerships with pharmaceutical firms to advance the formation of a value chain and speed up market growth. For instance, in June 2023, to develop a novel test for the detection of tumor cells that metastatic cancers shed into the blood, the University of Washington School of Medicine collaborated with RareCyte, Inc. which is a biotech company headquartered in Seattle. In addition, according to the research, the understanding of the circulating tumor cells in the bloodstream can track the changes in tumor cells, thus optimizing the treatment.

Request a free sample copy or view report summary: Circulating Tumor Cells Market Report

Circulating Tumor Cells Market Report Highlights

• Based on the technology, the CTC detection & enrichment methods dominated the market in 2022 with a revenue share of 65.3%owing to the increased availability of products for CTC enrichment and isolation as well as high usage and product penetration across the globe
• The growing application potential of CTC analysis for investigational research, drug development, and biomarker studies will result in the segment's highest CAGR from 2023 to 2030
• Based on application, the research segment accounted for the largest share in 2022 and is projected to grow at the fastest CAGR during the forecast period. This is attributed to the growing number of research studies for better treatment of cancer
• Based on product, the devices and systems segment dominated the market with a revenue share of 43.0% in 2022 owing to the presence of highly efficient automated systems and high usage of systems for the detection of tumor cells
• The whole blood specimens are the key source of circulating tumor cells. As a result, the segment has accounted for the largest revenue share of 46.5% in 2022. The blood specimen segment is also projected to exhibit a significant growth rate during the forecast period

Access Press Release@ https://www.grandviewresearch.com/press-release/global-circulating-tumor-cells-market

Circulating Tumor Cells Market Segmentation

Grand View Research has segmented the global circulating tumor cells market based on technology, application, product, specimen, and region:

Circulating Tumor Cells Technology Outlook (USD Million, 2018 - 2030)

• CTC Detection & Enrichment Methods
  • Immunocapture (Label-based)
    • Positive Selection
    • Negative Selection
  • Size-based Separation (Label-free)
    • Membrane-based
    • Microfluidic-based
  • Density-based Separation (Label-free)
  • Combined Methods (Label-free)
• CTC Direct Detection Methods
  • SERS
  • Microscopy
  • Others
• CTC Analysis

Circulating Tumor Cells Application Outlook (USD Million, 2018 - 2030)

• Clinical/Liquid Biopsy
  • Risk Assessment
  • Screening and Monitoring
• Research
  • Cancer Stem Cell & Tumorogenesis Research
  • Drug/Therapy Development

Circulating Tumor Cells Product Outlook (USD Million, 2018 - 2030)

• Kits & Reagents
• Blood Collection Tubes
• Devices or Systems

Circulating Tumor Cells Specimen Outlook (USD Million, 2018 - 2030)

• Blood
• Bone Marrow
• Other Body Fluids

Circulating Tumor Cells Regional Outlook (USD Million, 2018 - 2030)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

List of Key Players in the Circulating Tumor Cells Market

• QIAGEN
• Bio-Techne Corporation
• Precision for Medicine
• AVIVA Biosciences
• BIOCEPT, Inc.
• BioCEP Ltd.
• Fluxion Biosciences, Inc.
• Greiner Bio One International GmbH
• Ikonisys Inc.
• Miltenyi Biotec
• IVDiagnostics
• BioFluidica
• Canopus Bioscience Ltd.
• Biolidics Limited
• Creativ MicroTech, Inc.
• LungLife AI, Inc.
• Epic Sciences
• Rarecells Diagnostics
• ScreenCell
• Menarini Silicon Biosystems
• LineaRx, Inc. (Vitatex, Inc.)
• Sysmex Corporation
• STEMCELL Technologies, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.